Big pharma turns to AI to speed drug discovery, GSK signs deal

This post was originally published on this site

LONDON (Reuters) – The world’s leading drug companies are turning to artificial intelligence to improve the hit-and-miss business of finding new medicines, with GlaxoSmithKline unveiling a new $43 million deal in the field on Sunday.